Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Other Non-Current Liabilities (2016 - 2026)

Gyre Therapeutics has reported Other Non-Current Liabilities over the past 7 years, most recently at $1.4 million for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 86.38% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, down 86.38% year-over-year, with the annual reading at $1.4 million for FY2025, 86.38% down from the prior year.
  • Other Non-Current Liabilities was $1.4 million for Q4 2025 at Gyre Therapeutics, down from $3.2 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $10.8 million in Q3 2024 and troughed at $55000.0 in Q4 2022.
  • The 4-year median for Other Non-Current Liabilities is $4.7 million (2023), against an average of $5.6 million.
  • Year-over-year, Other Non-Current Liabilities skyrocketed 8485.45% in 2023 and then crashed 86.38% in 2025.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $55000.0 in 2022, then skyrocketed by 8485.45% to $4.7 million in 2023, then skyrocketed by 125.1% to $10.6 million in 2024, then crashed by 86.38% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Other Non-Current Liabilities are $1.4 million (Q4 2025), $3.2 million (Q3 2025), and $3.2 million (Q2 2025).